KMT2A and acute myeloid leukemia: Interestingly, Xu et al. [189] have recently shown in an MLL-AF9 AML mouse model that nearly half of AML blasts in resting phase were observed within 0 to 4 μm from blood vessels, suggesting that quiescent leukaemic cells make cell–cell contact with ECs to evade therapy.